Rethinking the INN system for therapeutic antibodies.
In the context of a possible revision of the International Nonproprietary Names (INN) system of recombinant monoclonal antibodies, which is saturated, we propose several avenues of reflection driven by the primary goal of the INN, information of health-care professionals. Clinical considerations argue for an abandon of the substems A (target category) and B (origin category), which lengthen the INN without real added-value. On the contrary, new substems or suffixes are required to alert on the absence/presence of an Fc portion and/or multispecificity, which are essential from a pharmacological point of view. Moreover, we think it necessary to explicitly mention Fc variations since they could influence the pharmacology of these biopharmaceuticals, and hence their efficacy and side-effects. Besides indicating the subclass/isotype in the documents easily accessible to health care professionals, we propose to systematically describe both the natural variations (allotypes) by using the Gm (G marker) system, and the artificial variations by using a Ge (G engineering) system that is discussed here and could apply to all IgG constant domains (tentatively called the Fy portion).
a Université François Rabelais , Tours , France.|b UMR 7292 , Tours , France.
Jérémy
J
Pottier
a Université François Rabelais , Tours , France.|b UMR 7292 , Tours , France.
Romane
R
Chastang
a Université François Rabelais , Tours , France.|b UMR 7292 , Tours , France.
Christophe
C
Dumet
a Université François Rabelais , Tours , France.|b UMR 7292 , Tours , France.|c CHRU de Tours, Service d'immunologie , Tours , France.
Hervé
H
Watier
D000818:Animals; D000911:Antibodies, Monoclonal; D006801:Humans; D009626:Terminology as Topic
D000911:Antibodies, Monoclonal
Allotypes; Fc portion; INN; IgG; International Nonproprietary Name; bispecific; monoclonal antibody; pharmacokinetics; recombinant; variants